Cure SMA
Biogen Provides SMA Community Update on DEVOTE Study
Below we have provided an update from Biogen regarding the status of its DEVOTE clinical trial. For more information about SPINRAZA (nusinersen), visit https://www.curesma.org/spinraza/.
++++++++++++++++++++
Biogen’s DEVOTE study is designed to evaluate the safety, tolerability, and potential for even greater efficacy of SPINRAZA when administered at a higher dose than currently approved for the treatment of spinal muscular atrophy (SMA). The Phase 2/3 randomized, controlled, dose-escalating study will be conducted at approximately 60 sites in 26 countries around the world, and aims to enroll 152 individuals of all ages with SMA.